NCT06515418Phase 2Terminated

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-02-06Actual

Enrollment · participants204Actual

Source updated2025-03-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Obesity

Treatments or interventions studied

Oral Azelaprag (BGE-105)DrugAlso known as BGE-105
Oral Placebo for Azelaprag (BGE-105)DrugAlso known as Placebo
TirzepatideDrug
Tirzepatide PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Mean Percent Change in Body Weight (Azelaprag Once per Day); description: Mean percent change in body weight from baseline to Week 24 in the 300 mg azelaprag once per day (QD) plus tirzepatide arm compared to tirzepatide alone arm; timeFrame: Week 24; measure: Mean Percent Change in Body Weight (Azelaprag Twice per Day); description: Mean percent change in body weight from baseline to Week 24 in the 300 mg azelaprag twice per day (BID) plus tirzepatide arm compared to tirzepatide alone arm; timeFrame: Week 24

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history